Today’s guest post comes from Jan Nielsen, Patient Solutions Division President at AssistRx. Jan discusses the challenges facing life sciences organizations’ patient support program reverification processes. Jan then highlights how the right vendor can help overcome these challenges for both pharmacy and medical benefit products. She offers real-world examples how of AssistRx implements these solutions for clients. To learn more about AssistRx’s solutions for medical benefit products, read their latest case study: eMedical Benefit Verification: Improving Speed to Therapy and Patient & ..read more

Summer unofficially began over the weekend. Let’s turn up the heat with these sizzling news bites, seared to perfection on the Drug Channels grill: CVS Health’s Cordavis business seems to want quasi-regulatory oversight of Humira biosimilars 340B’s skyrocketing growth continues, but the market is changing Plans sponsors' fading interest in alternative funding programs A post-Asembia review from DCI’s trip to Las Vegas Plus, South Park goes after insurance companies and PBMs over GLP-1 coverage. P.S. Join my nearly 56,000 LinkedIn followers for daily links to neat stuff. Register no ..read more

In my recent Drug Channel Implications of the Inflation Reduction Act video webinar, I explained the intended and unintended consequences of the Inflation Reduction Act of 2022 (IRA) for the commercial market and drug channel participants. In the video excerpt below, I walk through a mathematical example to show why the IRA will encourage Part D plans to prefer high-list, high-rebate specialty drugs, even as the government and manufacturers will prefer a low-list-price version. What’s more, a product with a maximum fair price (MFP) may also raise total costs for the healthcare system—despite ..read more

Dr. Adam J. Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for DCI’s new live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook This event will be broadcast live on Friday, June 21, 2024, from 12:00 p.m. to 1:30 p.m. ET This page describes the event and explains how to purchase a registration. The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia. This event is part of The Drug Channels 2024 Video Webinar Series. WHAT YOU WILL LEARN The federal 340B Drug Pr ..read more

Contrary to what you may have heard, the Inflation Reduction Act’s (IRA) inflation rebates for Medicare Part B drugs do not always save money for seniors. As we document below, a growing share of Part B drugs have inflation-adjusted coinsurance rates that have been increasing, not declining. In many cases, the coinsurance rate declines only briefly before rebounding back to the standard 20% rate. What’s more, these fluctuations have triggered huge jumps in patients’ out-of-pocket obligations for some drugs—even when a drug’s costs were falling. Chalk off these coinsurance surprises to yet ..read more

Today’s guest post comes from Hannah Baxter, Associate Partner at The Dedham Group; Jen Klarer, Partner, Head of Cell & Gene Therapy at The Dedham Group; and Carolyn Zele, Advisor, Solution Consulting at MMIT. The authors discuss the access barriers facing patients who need biomarker testing. They discuss five ways manufacturers can prevent these barriers from affecting patients. To learn more about navigating the complexities of market access, contact MMIT and its sister company, The Dedham Group. Read on for their insights. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Chan ..read more

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Chris explains how the Inflation Reduction Act of 2022 (IRA) will impact hub, patient assistance programs (PAP), and affordability programs. He discusses steps manufacturers can take to accommodate the anticipated budget reductions while maintaining access and affordability for patients. To learn more, join Chris on May 21 at 1:00 p.m. ET for a free online panel discussion about how brands can continue to offer robust patient support despite IRA challenges. Read on for Chris’ insights. Read more ..read more

April is over, so it's time to hop into this month’s selection of noteworthy news: CVS Health’s formulary boosts a Humira biosimilar An insurer ditches buy-and-bill to save money for plans—but maybe not for patients? My $0.02 on how Medicare Part D plans will react to the Inflation Reduction Act Walgreens' unexpected specialty pharmacy strength A video deconstruction of my infamous Drug Channels article on GoodRx Plus, a cartoonist illustrates my recent keynote on the battle for oncology margin. P.S. Join my nearly 55,000 LinkedIn followers for daily links to neat stuff. Read more ..read more

Today’s guest post comes from Kevin Kettler, President of CoverMyMeds. Kevin asks: What if there were no barriers across the therapy access and reimbursement process? In his view, eliminating barriers requires a combination of expert insight, actionable data, and simplification of the providers' experiences. Click here to learn more about CoverMyMeds’ comprehensive technology solutions. Meet CoverMyMeds in Booth 1305 at the Asembia AXS24 Summit. To keep up with CoverMyMeds and all the action at Asembia, click here to sign up for daily recaps from Asembia. Read on for Kevin’s insights. Re ..read more

Next week, the Drug Channels Institute team will be attending Asembia’s AXS24 Summit at the wonderful Wynn Las Vegas. And for the first time—thanks to our new friends at HMP Global—DCI will have its very own booth! (Click here for a special sneak peek.) As you might expect, we will hit Vegas in true Drug Channels style. Stop by booth #1801 for fun and games: Partake in a special in-person Ask Me Anything with Adam (#AMAWA) session with DCI president Adam J. Fein, Ph.D.! The AMAWA session will start on Monday, April 29, at 4:30 p.m. (Bring your phone if you want a selfie!) Adam won’t be ..read more